| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
The biological targets of (25R)-Spirost-4-ene-3,12-dione are not fully characterized, but the compound has demonstrated inhibitory effects on neutrophil superoxide anion production and histamine release from mast cells. These activities suggest that the compound may interact with signaling pathways involved in inflammatory responses and allergic reactions. The spirostan backbone is characteristic of steroidal sapogenins, which are known to have various biological activities including anti-inflammatory, anticancer, and cardiovascular effects. The compound's 3,12-dione functional groups contribute to its reactivity and potential interactions with biological targets. As a steroidal compound, it may interact with steroid receptors or other proteins involved in steroid hormone signaling. However, specific molecular targets have not been definitively identified in the available literature. The compound is primarily used as a chemical intermediate and research tool for studying steroid chemistry and pharmacology.
|
|---|---|
| ln Vitro |
In vitro, (25R)-Spirost-4-ene-3,12-dione has been shown to inhibit neutrophil superoxide anion production and histamine release from mast cells. These activities indicate potential anti-inflammatory and anti-allergic properties. The compound's effects on neutrophil function suggest it may modulate the respiratory burst and inflammatory mediator release. In mast cells, inhibition of histamine release indicates potential anti-allergic activity. The compound's spirostan structure is characteristic of steroidal sapogenins, which are known to have various biological activities. However, detailed in vitro characterization including dose-response relationships, mechanism of action, and potency have not been extensively reported. The compound is primarily used as a chemical intermediate and research tool. Its in vitro activities make it of interest for studying inflammation, allergy, and steroid pharmacology.
|
| ln Vivo |
In vivo studies with (25R)-Spirost-4-ene-3,12-dione are limited in publicly available literature. As a natural product with inhibitory effects on neutrophil superoxide anion production and mast cell histamine release, the compound may have potential anti-inflammatory and anti-allergic effects in vivo, but specific animal studies have not been extensively reported. The compound's steroidal structure suggests it may have hormonal or endocrine effects, but these have not been characterized. The compound is primarily used as a chemical intermediate and research tool. Researchers interested in in vivo applications should consult the primary literature for updated information and conduct appropriate studies to determine efficacy, dosing, and safety. The compound's role in steroidal saponin synthesis suggests it may have applications in developing steroid-based therapeutics.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for (25R)-Spirost-4-ene-3,12-dione are not extensively documented. The compound's effects on neutrophil superoxide anion production and mast cell histamine release have been reported, suggesting interactions with cellular signaling pathways. Neutrophil superoxide anion production can be measured using assays such as cytochrome c reduction or luminol-enhanced chemiluminescence. Mast cell histamine release can be measured by ELISA or radioimmunoassay. These assays would be used to characterize the compound's inhibitory activity and determine potency. However, specific molecular targets (enzyme or receptor) have not been identified. The compound's steroidal structure suggests it may interact with steroid receptors, but this has not been confirmed. Researchers should consult primary literature for specific assay protocols.
|
| Cell Assay |
Cell-based assays for (25R)-Spirost-4-ene-3,12-dione would focus on its inhibitory effects on neutrophil superoxide anion production and mast cell histamine release. Neutrophils or mast cells would be isolated from appropriate sources (e.g., human blood or rodent tissues) and treated with the compound at various concentrations. Neutrophils would be stimulated with phorbol esters or other activators, and superoxide anion production would be measured by cytochrome c reduction or chemiluminescence. Mast cells would be stimulated with IgE/antigen or calcium ionophores, and histamine release would be measured by ELISA or fluorescence-based assays. These cell-based assays would characterize the compound's anti-inflammatory and anti-allergic activities. However, specific detailed protocols are not well-documented in the available literature. Researchers should develop appropriate assays based on the compound's reported activities.
|
| Animal Protocol |
In vivo animal protocols for (25R)-Spirost-4-ene-3,12-dione are not documented in publicly available literature. As a natural product with anti-inflammatory and anti-allergic potential, typical study designs would involve administration of the compound in rodent models of inflammation (e.g., carrageenan-induced paw edema) or allergy (e.g., passive cutaneous anaphylaxis). Doses would be determined from in vitro potency data and preliminary toxicity assessments. Route of administration would depend on the compound's solubility and bioavailability. Endpoints would include inflammatory markers, histamine levels, and behavioral or physiological responses. However, no specific in vivo protocols have been reported. Researchers should consult primary literature and conduct appropriate studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (25R)-Spirost-4-ene-3,12-dione have not been characterized in publicly available literature. The compound has molecular weight 426.59 and molecular formula C27H38O4. As a steroidal compound, it is expected to have moderate lipophilicity and may be orally bioavailable, but empirical data are lacking. The compound is a solid and should be stored at -20°C for up to 3 years. Solubility data are not extensively reported. The compound is primarily used as a chemical intermediate and research tool, and its pharmacokinetic properties have not been a focus of study. Researchers planning in vivo studies should conduct appropriate pharmacokinetic characterization to determine absorption, distribution, metabolism, and excretion parameters.
|
| Toxicity/Toxicokinetics |
Toxicology data for (25R)-Spirost-4-ene-3,12-dione are not available in the public domain. As a natural product and steroidal compound, potential toxicities would depend on dose, route of administration, and duration of exposure. The compound is for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. The compound should be stored properly and disposed of in accordance with applicable regulations. Researchers should consult the material safety data sheet (MSDS) for detailed safety information. No specific toxicity data (LD50, organ-specific toxicity, genotoxicity, etc.) have been reported. Appropriate toxicity studies should be conducted if the compound is to be used in vivo.
|
| References | |
| Additional Infomation |
Reports indicate that Polygonum and Tribulus contain (25R)-spirost-4-ene-3,12-dione, and relevant data are available for reference.
(25R)-Spirost-4-ene-3,12-dione has CAS number 6875-60-1, molecular formula C27H38O4, and molecular weight 426.59. It is a naturally occurring steroidal sapogenin with a spirostan backbone, also known as a spirostan-type steroid. The compound is characterized by a 4-ene-3,12-dione functional group configuration. It has been shown to inhibit neutrophil superoxide anion production and histamine release from mast cells. The compound is widely used in pharmaceutical research, steroid chemistry, and drug discovery as a key intermediate in the synthesis of bioactive steroids and saponins. It plays a role in developing anti-inflammatory, anticancer, and cardiovascular agents. The compound is particularly valuable in hormonal regulation studies, medicinal chemistry, and the synthesis of steroid-based therapeutics. Purity: ≥95%. Storage: -20°C for up to 3 years. Not approved for clinical use; for research purposes only. |
| Molecular Formula |
C27H38O4
|
|---|---|
| Molecular Weight |
426.59
|
| Exact Mass |
426.277
|
| CAS # |
6875-60-1
|
| PubChem CID |
10836200
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.101
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
31
|
| Complexity |
861
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(C(=O)C[C@H]5[C@H]4CCC6=CC(=O)CC[C@]56C)C)C)OC1
|
| InChi Key |
ZVWYBBDTSJOAHD-HGMFYQPQSA-N
|
| InChi Code |
InChI=1S/C27H38O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)12-21-19-6-5-17-11-18(28)8-9-25(17,3)20(19)13-23(29)26(21,24)4/h11,15-16,19-22,24H,5-10,12-14H2,1-4H3/t15-,16+,19-,20+,21+,22+,24+,25+,26-,27-/m1/s1
|
| Chemical Name |
(1R,2S,4S,5'R,6R,7S,8R,9S,12S,13R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-ene-6,2'-oxane]-10,16-dione
|
| Synonyms |
(-)-(25R)-Spirost-4-ene-3,12-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3442 mL | 11.7209 mL | 23.4417 mL | |
| 5 mM | 0.4688 mL | 2.3442 mL | 4.6883 mL | |
| 10 mM | 0.2344 mL | 1.1721 mL | 2.3442 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
